Pharmacological FAK inhibition reduced the expression of monocyte chemoattractant protein-1, matrix metalloproteinase-9 (MMP-9), and MMP-2, in human AAA tissue samples ex vivo [87], suggesting that FAK activity in VSMCs may drive sustained inflammation in AAAs. The gene discussed is MMP9; the disease is achalasia-alacrima syndrome.